If you suffered from an adverse reaction to a Victoza medication, you may be entitled to file a lawsuit. If you did, you should seek medical advice from an expert. Expert medical opinions are necessary to prove that Victoza caused your injuries. You should also retain the services of an attorney specializing in Victoza lawsuits. This article discusses the various medical aspects of the lawsuit process. It will also cover a few other topics, including Bristol Myers Squibb and Novo Nordisk.
Novo Nordisk
In March 2017, Novo Nordisk filed a patent litigation lawsuit against generic drugmaker Teva Pharmaceuticals. The lawsuit alleged that Teva was infringing on Novo’s Victoza patent. While the FDA approved the generic version of Victoza in July 2016, Novo sued in April and won, forcing Teva to delay the launch of its generic until at least December 2023. In addition, the company is requiring generic drugmakers to wait until June 2024 before they can launch their versions of Victoza.
The drugmaker recently announced a settlement with a whistleblower. The settlement will settle seven separate lawsuits against the drugmaker. The settlement also includes a whistleblower provision that allows private parties to sue on behalf of the United States. Ultimately, Novo Nordisk will pay $46.5 million to settle the lawsuits, which arose out of seven whistleblower lawsuits. The settlement does not address the specific allegations in the lawsuit, but the agreement will help victims get compensation.
In August 2013, the Judicial Panel on Multidistrict Litigation transferred 53 cases against Novo Nordisk to MDL 2452. These cases originated in state courts in Arizona, Colorado, Kansas, Oklahoma, and Pennsylvania. The plaintiffs allege that Victoza caused several health problems, including pancreatic cancer and pancreatitis. In addition to the FDA-mandated REMS, Novo Nordisk was required to provide physicians with information about its potential risk of MTC. The failure to comply with the REMS rendered the drug misbranded.
Amylin
In the recent Amylin in Victoza lawsuit, the FDA has disclaimed an alleged statement that the drug causes pancreatic cancer as a consequence of prolonged use. The agency asserts that it has no new evidence to support a change in the drug’s label, based on non-assigned articles and speeches. In addition, the FDA acknowledges that responding to citizen petitions falls within its regulatory authority.
This multidistrict litigation is made up of 97 cases involving cancers of the pancreas. These cases allege that four commonly prescribed drugs, including Victoza, increase the risk of pancreatic cancer. The plaintiffs are seeking damages for their suffering, which they believe has resulted from taking the drug. The lawsuits are based on the manufacturers’ failure to warn patients about this potential side effect.
The FDA approved Victoza as an approved treatment for type 2 diabetes in 2000, making it the first non-insulin drug approved for pediatric use. Since then, however, the FDA has approved three new incretin-based diabetes drugs without mentioning the possibility of pancreatic cancer. The company has defended its actions by approving various labeling changes, including the approval of sitagliptin in June 2019 and exenatide in February 2020.
Bristol Myers Squibb
The UMB Bank, the trustee for the former shareholders of Celgene, has filed a lawsuit against Bristol Myers Squibb for delaying the development and manufacturing of a cancer drug, Liso-cel. This drug, also known as Breyanzi, treats the most common form of non-Hodgkin’s lymphoma. Celgene created the drug, and Bristol Myers Squibb acquired the company in November 2019.
In response to the litigation, Bristol-Myers Squibb recently sold its diabetes division to AstraZeneca for $4.1 billion. The acquisition includes the diabetes drug line, Byetta, and Byron. The move will result in the loss of 4,100 jobs for Bristol-Myers Squibb employees. However, the acquisition has several downsides for those affected by the decision.
In August 2013, the U.S. Judicial Panel on Multidistrict Litigation (MDL) was established to coordinate proceedings in the federal courts. In this case, pancreatic cancer lawsuits filed in different states were consolidated before U.S. District Judge Anthony J. Battaglia in the Southern District of California. The MDL reduced duplicative discovery, avoided conflicting pretrial rulings, and was created for the convenience of both parties and witnesses.
